Ellen Donnelly
Chief Executive Officer chez ABLIVA AB
Profil
Ellen K.
Donnelly is currently the Chief Executive Officer at Abliva AB.
She is also an Independent Director at Modus Therapeutics Holding AB.
In addition, she serves as an Independent Director at AlzeCure Pharma AB and as a Director at Modus Therapeutics AB.
Previously, she held the position of Chief Executive Officer-Epigenetics Division at Juvenescence Ltd.
Dr. Donnelly obtained a doctorate degree from Yale School of Medicine.
Postes actifs de Ellen Donnelly
| Sociétés | Poste | Début |
|---|---|---|
| ALZECURE PHARMA AB | Director/Board Member | 01/01/2018 |
| MODUS THERAPEUTICS HOLDING AB | Director/Board Member | 01/01/2020 |
| ABLIVA AB | Chief Executive Officer | 03/02/2021 |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Director/Board Member | 01/01/2019 |
Anciens postes connus de Ellen Donnelly
| Sociétés | Poste | Fin |
|---|---|---|
Juvenescence Ltd.
 Juvenescence Ltd. Financial ConglomeratesFinance Juvenescence Ltd. engages in operation as an investment holding company which develops therapeutic products for human ageing and longevity. It provides drug development, new company creation, academic licensing, and biotech investment. The company was founded by James Mellon, Gregory H. Bailey, Declan Dooganin, Alexander Pickett, and Anthony Chow in October 2016 and is headquartered in Liverpool, the United Kingdom. | Corporate Officer/Principal | - |
Formation de Ellen Donnelly
| Yale School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ABLIVA AB | Health Technology |
| MODUS THERAPEUTICS HOLDING AB | Health Technology |
| ALZECURE PHARMA AB | Health Technology |
| Entreprise privées | 2 |
|---|---|
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Health Technology |
Juvenescence Ltd.
Juvenescence Ltd. Financial ConglomeratesFinance Juvenescence Ltd. engages in operation as an investment holding company which develops therapeutic products for human ageing and longevity. It provides drug development, new company creation, academic licensing, and biotech investment. The company was founded by James Mellon, Gregory H. Bailey, Declan Dooganin, Alexander Pickett, and Anthony Chow in October 2016 and is headquartered in Liverpool, the United Kingdom. | Finance |
